Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis
Graf T, Thiele T, Klingebiel R, Greinacher A, Schäbitz W-R, Greeve I (2021)
Journal of Neurology 268(12): 4483-4485.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
Autor*in
Graf, Tilmann;
Thiele, Thomas;
Klingebiel, Randolf;
Greinacher, Andreas;
Schäbitz, Wolf-RüdigerUniBi;
Greeve, IsabellUniBi
Einrichtung
Erscheinungsjahr
2021
Zeitschriftentitel
Journal of Neurology
Band
268
Ausgabe
12
Seite(n)
4483-4485
Urheberrecht / Lizenzen
ISSN
0340-5354
eISSN
1432-1459
Finanzierungs-Informationen
Open-Access-Publikationskosten wurden durch die Universität Bielefeld im Rahmen des DEAL-Vertrags gefördert.
Page URI
https://pub.uni-bielefeld.de/record/2964825
Zitieren
Graf T, Thiele T, Klingebiel R, Greinacher A, Schäbitz W-R, Greeve I. Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. Journal of Neurology. 2021;268(12):4483-4485.
Graf, T., Thiele, T., Klingebiel, R., Greinacher, A., Schäbitz, W. - R., & Greeve, I. (2021). Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. Journal of Neurology, 268(12), 4483-4485. https://doi.org/10.1007/s00415-021-10599-2
Graf, Tilmann, Thiele, Thomas, Klingebiel, Randolf, Greinacher, Andreas, Schäbitz, Wolf-Rüdiger, and Greeve, Isabell. 2021. “Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis”. Journal of Neurology 268 (12): 4483-4485.
Graf, T., Thiele, T., Klingebiel, R., Greinacher, A., Schäbitz, W. - R., and Greeve, I. (2021). Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. Journal of Neurology 268, 4483-4485.
Graf, T., et al., 2021. Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. Journal of Neurology, 268(12), p 4483-4485.
T. Graf, et al., “Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis”, Journal of Neurology, vol. 268, 2021, pp. 4483-4485.
Graf, T., Thiele, T., Klingebiel, R., Greinacher, A., Schäbitz, W.-R., Greeve, I.: Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. Journal of Neurology. 268, 4483-4485 (2021).
Graf, Tilmann, Thiele, Thomas, Klingebiel, Randolf, Greinacher, Andreas, Schäbitz, Wolf-Rüdiger, and Greeve, Isabell. “Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis”. Journal of Neurology 268.12 (2021): 4483-4485.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Creative Commons Namensnennung 4.0 International Public License (CC-BY 4.0):
Volltext(e)
Name
Access Level
Open Access
Zuletzt Hochgeladen
2022-08-02T09:40:25Z
MD5 Prüfsumme
be483ce249da1e4a4fe114de94d5b49e
Daten bereitgestellt von European Bioinformatics Institute (EBI)
Zitationen in Europe PMC
Daten bereitgestellt von Europe PubMed Central.
References
Daten bereitgestellt von Europe PubMed Central.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Quellen
PMID: 34023956
PubMed | Europe PMC
Suchen in